Cargando…

Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis

Chronic active and slowly expanding lesions with smouldering inflammation are neuropathological correlates of progressive multiple sclerosis pathology. T(1) hypointense volume and signal intensity on T(1)-weighted MRI reflect brain tissue damage that may develop within newly formed acute focal infla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elliott, Colm, Belachew, Shibeshih, Wolinsky, Jerry S, Hauser, Stephen L, Kappos, Ludwig, Barkhof, Frederik, Bernasconi, Corrado, Fecker, Julian, Model, Fabian, Wei, Wei, Arnold, Douglas L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736181/ https://www.ncbi.nlm.nih.gov/pubmed/31497864 http://dx.doi.org/10.1093/brain/awz212

Ejemplares similares

Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions
por: Elliott, Colm, et al.
Publicado: (2018)

Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials
por: Kappos, Ludwig, et al.
Publicado: (2020)

Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial
por: Wolinsky, Jerry S., et al.
Publicado: (2018)

Recurrent disability progression endpoints in multiple sclerosis clinical trials
por: Bühler, Alexandra, et al.
Publicado: (2022)

Slowly expanding lesions are a marker of progressive MS – No
por: Arnold, Douglas L, et al.
Publicado: (2021)

Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension
por: Hauser, Stephen L., et al.
Publicado: (2020)

Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis
por: Barkhof, Frederik, et al.
Publicado: (2019)

Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial
por: Fox, Edward J, et al.
Publicado: (2018)

Chronic lesion activity and disability progression in secondary progressive multiple sclerosis
por: Beynon, Vanessa, et al.
Publicado: (2022)

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis
por: Hauser, Stephen L., et al.
Publicado: (2021)

Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis
por: Hauser, Stephen L., et al.
Publicado: (2023)

Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO
por: Gibiansky, Ekaterina, et al.
Publicado: (2020)

Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study
por: Kappos, Ludwig, et al.
Publicado: (2017)

Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials
por: Bar-Or, Amit, et al.
Publicado: (2023)

Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP)
por: Wiendl, Heinz, et al.
Publicado: (2016)

Glial fibrillary acidic protein and multiple sclerosis progression independent of acute inflammation
por: Jiang, Xiaotong, et al.
Publicado: (2023)

Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry
por: Butzkueven, Helmut, et al.
Publicado: (2021)

Serum Neurofilament Light and Multiple Sclerosis Progression Independent of Acute Inflammation
por: Gafson, Arie R., et al.
Publicado: (2022)

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
por: Butzkueven, Helmut, et al.
Publicado: (2014)

Abnormalities in normal-appearing white matter from which multiple sclerosis lesions arise
por: Elliott, Colm, et al.
Publicado: (2021)

Imaging outcome measures for progressive multiple sclerosis trials
por: Moccia, Marcello, et al.
Publicado: (2017)

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis
por: Turner, Benjamin, et al.
Publicado: (2019)

Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials
por: Giovannoni, Gavin, et al.
Publicado: (2021)

Lesion-level correspondence and longitudinal properties of paramagnetic rim and slowly expanding lesions in multiple sclerosis
por: Elliott, Colm, et al.
Publicado: (2023)

Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis
por: Chang, Ih, et al.
Publicado: (2022)

Preliminary validity of the Draw a Shape Test for upper extremity assessment in multiple sclerosis
por: Graves, Jennifer S., et al.
Publicado: (2022)

A smartphone sensor-based digital outcome assessment of multiple sclerosis
por: Montalban, Xavier, et al.
Publicado: (2021)

No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a
por: Havrdová, Eva, et al.
Publicado: (2018)

Adherence and Satisfaction of Smartphone- and Smartwatch-Based Remote Active Testing and Passive Monitoring in People With Multiple Sclerosis: Nonrandomized Interventional Feasibility Study
por: Midaglia, Luciana, et al.
Publicado: (2019)

Correction: Adherence and Satisfaction of Smartphone- and Smartwatch-Based Remote Active Testing and Passive Monitoring in People With Multiple Sclerosis: Nonrandomized Interventional Feasibility Study
por: Midaglia, Luciana, et al.
Publicado: (2019)

Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS
por: Arnold, Douglas L, et al.
Publicado: (2022)

Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes
por: Colato, Elisa, et al.
Publicado: (2021)

Brain atrophy and disability worsening in primary progressive multiple sclerosis: insights from the INFORMS study
por: Miller, David H., et al.
Publicado: (2018)

Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging
por: Kolind, Shannon, et al.
Publicado: (2023)

The spatio-temporal relationship between white matter lesion volume changes and brain atrophy in clinically isolated syndrome and early multiple sclerosis
por: Mattiesing, Rozemarijn M., et al.
Publicado: (2022)

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis
por: Cree, Bruce AC, et al.
Publicado: (2020)

Spinal cord atrophy in a primary progressive multiple sclerosis trial: Improved sample size using GBSI
por: Moccia, Marcello, et al.
Publicado: (2020)

Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials
por: Leppert, David, et al.
Publicado: (2022)

Progressive brain rich-club network disruption from clinically isolated syndrome towards multiple sclerosis
por: Shu, Ni, et al.
Publicado: (2018)

Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis
por: Radue, Ernst-Wilhelm, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fmagr51sjcrnf898udmdkspnja